Notification of Supply Interruption: Article 10/A of the Tıbbi Cihaz Yönetmeliği, Article 11/A of the IVD Yönetmeliği and Six Months’ Advance Notice

SUMMARY
Notification of a supply interruption is regulated in Article 10/A of the Tıbbi Cihaz Yönetmeliği (Medical Device Regulation). Where a manufacturer anticipates an interruption or discontinuation in the supply of a device, and it can reasonably be foreseen that this could result in serious harm or a risk of serious harm to patients or public health, it informs the Agency and the parties to which it directly supplies the device at least six months in advance.
The same provision for in vitro diagnostic devices is in Article 11/A of the IVD Yönetmeliği (In Vitro Diagnostic Medical Device Regulation). The article corresponds to Article 10a added to the MDR and IVDR by Regulation (EU) 2024/1860 and entered into force on 10/1/2025. In this article, the provision, the duty of the operators in the chain, the entry into force and the application to transitional devices are given as direct quotations.
For ÜTS registration and notification transactions of your devices: Medical Device ÜTS Registration Consultancy
Contents
1. Article 10/A: The Case in Which the Obligation Arises
The article was added by the amendment published in the Official Gazette (No. 32635) of 17 August 2024. Its title and subparagraph (a) of the first paragraph:
“Obligations in case of interruption or discontinuation of the supply of certain devices ARTICLE 10/A- (Added: Official Gazette 17/8/2024-32635)(5)”
“(a) Where a manufacturer anticipates an interruption or discontinuation in the supply of a device other than a custom-made device, and it is reasonably foreseeable that such an interruption or discontinuation could result in serious harm or a risk of serious harm to patients or public health in Türkiye or in one or more EU Member States, the manufacturer shall inform the Agency, and also the economic operators, health institutions and healthcare professionals to which it directly supplies the device, of the anticipated interruption or discontinuation.”
Obliged party: the manufacturer.
Scope: devices other than custom-made devices.
Event: an anticipated interruption or discontinuation in supply.
Threshold: it being reasonably foreseeable that it could result in serious harm or a risk of serious harm to patients or public health in Türkiye or in one or more EU Member States.
Addressee: the Agency, and the economic operators, health institutions and healthcare professionals to which it directly supplies the device.
For the general obligations of the manufacturer, see our article on manufacturer general obligations, and for custom-made devices, our article on custom-made device.
2. The Six-Month Period and the Justification Requirement
Subparagraph (b) of the first paragraph sets the period and the content of the information to be given to the Agency:
“(b) Except in exceptional circumstances, the information referred to in subparagraph (a) shall be provided no later than six months before the anticipated interruption or discontinuation. The manufacturer shall clearly state the reasons for the interruption or discontinuation in the information provided to the Agency.”
The period is at least six months before the anticipated interruption or discontinuation.
Exceptional circumstances are excluded from this period.
The reasons for the interruption or discontinuation are clearly stated in the information given to the Agency.
The Regulation does not list in this article what the exceptional circumstances are or in what format the information is to be given.
3. The Duty of the Agency
Under the second paragraph, the information is not limited to Türkiye:
“(2) After receiving the information referred to in the first paragraph, the Agency shall, without delay, inform the competent authorities of the other EU Member States and the Commission of the anticipated interruption or discontinuation.”
4. The Duty of Operators in the Supply Chain
The third paragraph also gives a duty to importers, distributors and other economic operators that receive the information:
“(3) Economic operators that receive information from the manufacturer or from another economic operator in the supply chain under the first paragraph shall, without delay, inform the other economic operators, health institutions and healthcare professionals to which they directly supply the device of the anticipated interruption or discontinuation.”
Knowing to whom a device was supplied rests on the traceability obligation in Article 25:
“(2) Economic operators shall be able to present the following to the Agency and, where the device is made available on the EU market, to the competent authorities of the relevant EU Member States, for the period referred to in the eighth paragraph of Article 10:”
“(a) any economic operator to whom they have directly supplied a device,”
“(b) any economic operator who has directly supplied them with a device,”
“(c) any health institution or healthcare professional to which they have directly supplied a device.”
For the other duties of importers and distributors, see our article on importer and distributor obligations, and for traceability, our article on supply chain and traceability.
5. IVD Yönetmeliği (In Vitro Diagnostic Medical Device Regulation): Article 11/A
For in vitro diagnostic devices, the same obligation is in Article 11/A:
“(a) Where a manufacturer anticipates an interruption or discontinuation in the supply of a device, and it is reasonably foreseeable that such an interruption or discontinuation could result in serious harm or a risk of serious harm to patients or public health in Türkiye or in one or more EU Member States, the manufacturer shall inform the Agency, and also the economic operators, health institutions and healthcare professionals to which it directly supplies the device, of the anticipated interruption or discontinuation.”
Subparagraph (a) of Article 11/A has no custom-made device exception. The six-month period in subparagraph (b), the justification requirement and the second and third paragraphs are the same text as in Article 10/A.
6. Date of Entry into Force: 10/1/2025
Footnote (5) on the addition of Article 10/A:
“(5) This amendment enters into force on 10/1/2025.”
Footnote (6) on Article 11/A in the IVD Yönetmeliği also gives the same date:
“(6) This amendment enters into force on 10/1/2025.”
Article 3 of Regulation (EU) 2024/1860 also provides the same date of application for the provisions of Article 10a:
“Article 1, point (1), and Article 2, point (1), shall apply from 10 January 2025.”
7. Application to Devices under Transitional Provisions
The provision is not limited to devices certified under the new regulation. Paragraph sixteen of provisional Article 1 of the Tıbbi Cihaz Yönetmeliği (Medical Device Regulation):
“(16) (Added: Official Gazette 17/8/2024-32635)(4) Article 10/A also applies to the devices referred to in subparagraphs (b) and (c) of the fifth paragraph.”
Subparagraph (b) of the fifth paragraph covers devices with a valid certificate issued under the old regulation; subparagraph (c) covers devices for which a declaration of conformity was drawn up before 26/5/2021 and which require the involvement of a notified body under the new regulation:
“(b) devices with a certificate issued under the Medical Device Regulation or the Active Implantable Medical Devices Regulation repealed by Article 110 and valid under the fourth paragraph may be placed on the market or put into service until the following dates:”
The equivalent in the IVD Yönetmeliği is paragraph sixteen of provisional Article 1:
“(16) (Added: Official Gazette 17/8/2024-32635)(5) Article 11/A also applies to the devices referred to in subparagraphs (b) and (c) of the fourth paragraph.”
For the transitional dates, see our articles on the Regulation (EU) 2023/607 MDR transition schedule and the Regulation (EU) 2024/1860 IVDR transition schedule.
8. Regulation (EU) 2024/1860 and Article 10a
The amendment to the Regulation was prepared taking Regulation (EU) 2024/1860 into account. The relevant subparagraph in Article 109 (Harmonization with European Union legislation) of the Tıbbi Cihaz Yönetmeliği:
“(ğ) (Added: Official Gazette 17/8/2024-32635) Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13/6/2024 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the gradual roll-out of Eudamed, the obligation to inform in case of interruption of supply and transitional provisions for certain in vitro diagnostic medical devices,”
The first paragraph of Article 10a added to the MDR:
“Where a manufacturer anticipates an interruption or a discontinuation of the supply of a device, other than a custom-made device, and where it is reasonably foreseeable that such interruption or discontinuation could result in serious harm or a risk of serious harm to patients or public health in one or more Member States, the manufacturer shall inform the competent authority of the Member State where it or its authorised representative is established, as well as the economic operators, health institutions and healthcare professionals to whom it directly supplies the device, of the anticipated interruption or discontinuation.”
In the EU text, the addressee is the competent authority of the Member State where the manufacturer or its authorized representative is established; in the Turkish regulation, this addressee is the Agency. Recital 15 of the Regulation gives examples of the situations from which the risk of serious harm can arise:
“The risk of serious harm to patients or public health can, for example, be due to the relevance of such devices for ensuring essential healthcare services in one or more Member States, the dependency of patient health and safety on the continuous availability of such devices in one or more Member States, or the absence of suitable alternatives, also in light of the expected length of the interruption, the quantities of devices already made available on the market and available stocks or timelines for procuring alternatives for such devices.”
According to the text of the recital, the information is passed along the chain until it reaches the health institution:
“The information should be provided by the manufacturer and other economic operators in the downstream supply chain until it reaches the relevant health institutions or healthcare professionals.”
9. Its Place in the ÜTS Registration Guide
Article 48 of the TCKKD-KLVZ-03 ÜTS registration guide includes this obligation when listing the purposes of Regulation (EU) 2024/1860:
“The introduction of a new obligation to give advance notice, where an interruption in the supply of devices under the MDR and IVDR that is assessed as posing a risk of serious danger to patients or public health in the event of an interruption in supply is anticipated.”
The Guide does not describe a separate ÜTS screen for the 10/A notification. Under Article 34 of the Tıbbi Cihaz Yönetmeliği, ÜTS obligations are determined by the Agency’s regulations:
“(2) The said obligations relating to ÜTS are determined by the regulations published by the Agency.”
Article 10/A is a separate obligation from serious adverse event notification. For vigilance notifications, see our article on vigilance and serious adverse event reporting, for ÜTS movement notifications, our article on ÜTS individual movement notifications; and for ÜTS notification transactions, see our page on the ÜTS individual notification service.
10. Frequently Asked Questions
How far in advance is a supply interruption notified?
Under subparagraph (b) of the first paragraph of Article 10/A, except in exceptional circumstances, at least six months before the anticipated interruption or discontinuation.
Is every supply interruption notified?
No. The obligation arises where it is reasonably foreseeable that the interruption could result in serious harm or a risk of serious harm to patients or public health in Türkiye or in one or more EU Member States.
To whom is the notification made?
The manufacturer informs the Agency and the economic operators, health institutions and healthcare professionals to which it directly supplies the device. The reasons are clearly stated in the information given to the Agency.
Do importers or distributors also have a duty?
Yes. Under the third paragraph of Article 10/A, economic operators that receive the information inform, without delay, the operators, health institutions and healthcare professionals to which they directly supply the device.
Are devices certified under the old directives covered?
Yes. Under paragraph sixteen of provisional Article 1, Article 10/A also applies to the devices in subparagraphs (b) and (c) of the fifth paragraph. The provision entered into force on 10/1/2025.
For ÜTS registration and notification transactions of your devices: Medical Device ÜTS Registration Consultancy
Sources



